Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$7.70
0.010.13%
At close: Jan 15, 4:00 PM EST
$7.68
-0.02-0.26%
After Hours: Jan 16, 4:00 PM EST
Comments
Loading...
Gyre Therapeutics Analyst Ratings and Price Targets | NASDAQ:GYRE | Benzinga
Gyre Therapeutics Inc has a consensus price target of $17 based on the ratings of 2 analysts. The high is $18 issued by HC Wainwright & Co. on August 26, 2025. The low is $16 issued by Jefferies on October 10, 2025. The 2 most-recent analyst ratings were released by Jefferies and HC Wainwright & Co. on October 10, 2025 and August 26, 2025, respectively. With an average price target of $17 between Jefferies and HC Wainwright & Co., there's an implied 121.35% upside for Gyre Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Gyre Therapeutics
FAQ
What is the target price for Gyre Therapeutics (GYRE) stock?
The latest price target for Gyre Therapeutics (NASDAQ:GYRE) was reported by Jefferies on October 10, 2025. The analyst firm set a price target for $16.00 expecting GYRE to rise to within 12 months (a possible 108.33% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Gyre Therapeutics (GYRE)?
The latest analyst rating for Gyre Therapeutics (NASDAQ:GYRE) was provided by Jefferies, and Gyre Therapeutics initiated their buy rating.
When was the last upgrade for Gyre Therapeutics (GYRE)?
There is no last upgrade for Gyre Therapeutics
When was the last downgrade for Gyre Therapeutics (GYRE)?
There is no last downgrade for Gyre Therapeutics.
When is the next analyst rating going to be posted or updated for Gyre Therapeutics (GYRE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gyre Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gyre Therapeutics was filed on October 10, 2025 so you should expect the next rating to be made available sometime around October 10, 2026.
Is the Analyst Rating Gyre Therapeutics (GYRE) correct?
While ratings are subjective and will change, the latest Gyre Therapeutics (GYRE) rating was a initiated with a price target of $0.00 to $16.00. The current price Gyre Therapeutics (GYRE) is trading at is $7.68, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
